Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, \>/=18 years of age
Chronic hepatitis C infection for at least 6 months duration
Hepatitis C genotype 1a or 1b
Patients must have discontinued prior hepatitis C treatment at least 12 weeks prior to enrollment in this study
Patient showed a previous null response to therapy as defined by \< 2 log10 IU/mL decrease in viral titer after at least 12 weeks of treatment with PEG-IFN/RBV
You may not be if
Hepatitis C infection with a genotype other than genotype 1a or 1b
Body mass index \<18 or \>/=36
Hepatitis A, hepatitis B, or HIV infection
Herbal remedies \</=1 month prior to the first dose of study drug
Clareo Health | A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C
